Vascular endothelial growth factor gene polymorphisms and renal cell carcinoma: A systematic review and meta‑analysis

Zhang,Yong; Li,Sheng; Xiao,Hou‑Qin; Hu,Zhao‑Xiong; Xu,Yan‑Cheng; Huang,Qi

doi:10.3892/ol.2013.1499

Vascular endothelial growth factor gene polymorphisms and renal cell carcinoma: A systematic review and meta‑analysis

Authors:
- Yong Zhang
- Sheng Li
- Hou‑Qin Xiao
- Zhao‑Xiong Hu
- Yan‑Cheng Xu
- Qi Huang
View Affiliations

Affiliations: Department of Endocrinology, Zhongnan Hospital, Wuhan University, Wuhan, Hubei 430071, P.R. China, Department of Urology, Zhongnan Hospital, Wuhan University, Wuhan, Hubei 430071, P.R. China, Department of Nephropathy, Taihe Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China
Published online on: July 29, 2013 https://doi.org/10.3892/ol.2013.1499
Pages: 1068-1078

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Renal cell carcinoma (RCC) accounts for 3% of all cancer‑related mortalities in adults. The risk factors for the development of RCC remain under investigation. Vascular endothelial growth factor (VEGF) is a key mediator of angiogenesis and is crucial for the development and metastasis of tumors, including RCC. VEGF gene polymorphisms may alter VEGF protein concentrations, affect the process of angiogenesis and may be involved in inter‑individual variation in carcinogenesis. In the present study, a systematic review and meta‑analysis were performed based on published case‑control studies in order to estimate the association between VEGF gene polymorphisms and the susceptibility to RCC. A total of five studies that involved eight polymorphisms and were published between January 2000 and December 2012 were identified from PubMed. The results of this systematic review and meta‑analysis indicate that the VEGF 936C/T, 1612G/A, ‑1154G/A, ‑2549I/D, ‑460T/C and 405G/C gene polymorphisms are not associated with the risk of RCC. There was no polymorphism in 702C/T and RCC and the ‑2578C/A gene polymorphism may be associated with an increased risk of RCC. However, due to the limitations of the present study, further high quality case‑control studies are warranted to confirm these findings.

View Figures

View References

1	Rini BI, Campbell SC and Escudier B: Renal cell carcinoma. Lancet. 373:1119–1132. 2009. View Article : Google Scholar : PubMed/NCBI
2	Gupta K, Miller JD, Li JZ, Russell MW and Charbonneau C: Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev. 34:193–205. 2008. View Article : Google Scholar : PubMed/NCBI
3	Hunt JD, van der Hel OL, McMillan GP, Boffetta P and Brennan P: Renal cell carcinoma in relation to cigarette smoking: meta-analysis of 24 studies. Int J Cancer. 114:101–108. 2005. View Article : Google Scholar : PubMed/NCBI
4	Bellocco R, Pasquali E, Rota M, et al: Alcohol drinking and risk of renal cell carcinoma: results of a meta-analysis. Ann Oncol. 23:2235–2244. 2012. View Article : Google Scholar : PubMed/NCBI
5	Bjørge T, Tretli S and Engeland A: Relation of height and body mass index to renal cell carcinoma in two million Norwegian men and women. Am J Epidemiol. 160:1168–1176. 2004.PubMed/NCBI
6	Bergström A, Hsieh CC, Lindblad P, Lu CM, Cook NR and Wolk A: Obesity and renal cell cancer - a quantitative review. Br J Cancer. 85:984–990. 2001.
7	McLaughlin JK, Chow WH, Mandel JS, et al: International renal-cell cancer study. VIII Role of diuretics, other anti-hypertensive medications and hypertension. Int J Cancer. 63:216–221. 1995. View Article : Google Scholar : PubMed/NCBI
8	Ferrara N: Vascular endothelial growth factor. Trends Cardiovasc Med. 3:244–250. 1993. View Article : Google Scholar
9	Ferrara N and Davis-Smyth T: The biology of vascular endothelial growth factor. Endocr Rev. 18:4–25. 1997. View Article : Google Scholar
10	Zhou LP, Luan H, Dong XH, Jin GJ, Man DL and Shang H: Vascular endothelial growth factor +936C/T polymorphism and gastric cancer risk: A meta-analysis. Exp Ther Med. 2:931–936. 2011.
11	Kleinrouweler CE, Wiegerinck MM, Ris-Stalpers C, et al; EBM CONNECT Collaboration. Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms-like tyrosine kinase 1 and soluble endoglin in the prediction of pre-eclampsia: a systematic review and meta-analysis. BJOG. 119:778–787. 2012. View Article : Google Scholar
12	Toulis KA, Goulis DG, Mintziori G, et al: Meta-analysis of cardiovascular disease risk markers in women with polycystic ovary syndrome. Hum Reprod Update. 17:741–760. 2011. View Article : Google Scholar : PubMed/NCBI
13	Lambrechts D, Poesen K, Fernández-Santiago R, et al: Meta-analysis of vascular endothelial growth factor variations in amyotrophic lateral sclerosis: increased susceptibility in male carriers of the −2578AA genotype. J Med Genet. 46:840–846. 2009.PubMed/NCBI
14	Banumathy G and Cairns P: Signaling pathways in renal cell carcinoma. Cancer Biol Ther. 10:658–664. 2010. View Article : Google Scholar : PubMed/NCBI
15	Abe A, Sato K, Habuchi T, et al: Single nucleotide polymorphisms in the 3′ untranslated region of vascular endothelial growth factor gene in Japanese population with or without renal cell carcinoma. Tohoku J Exp Med. 198:181–190. 2002.
16	Moher D, Liberati A, Tetzlaff J and Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 339:b25352009. View Article : Google Scholar
17	Higgins JP and Thompson SG: Quantifying heterogeneity in a meta-analysis. Stat Med. 21:1539–1558. 2002. View Article : Google Scholar : PubMed/NCBI
18	Higgins JP, Thompson SG, Deeks JJ and Altman DG: Measuring inconsistency in meta-analyses. BMJ. 327:557–560. 2003. View Article : Google Scholar : PubMed/NCBI
19	Ricketts C, Zeegers MP, Lubinski J and Maher ER: Analysis of germline variants in CDH1, IGFBP3, MMP1, MMP3, STK15 and VEGF in familial and sporadic renal cell carcinoma. PLoS One. 4:e60372009. View Article : Google Scholar : PubMed/NCBI
20	Bruyère F, Hovens CM, Marson MN, et al: VEGF polymorphisms are associated with an increasing risk of developing renal cell carcinoma. J Urol. 184:1273–1278. 2010.PubMed/NCBI
21	Ajaz S, Khaliq S, Abid A, et al: Association of a single-nucleotide polymorphism in the promoter region of the VEGF gene with the risk of renal cell carcinoma. Genet Test Mol Biomarkers. 15:653–657. 2011. View Article : Google Scholar : PubMed/NCBI
22	Sáenz-Lopez P, Vazquez F, Cozar JM, Carretero R, Garrido F and Ruiz-Cabello F: VEGF polymorphisms are not associated with an increased risk of developing renal cell carcinoma in Spanish population. Hum Immunol. 74:98–103. 2013.
23	Lutty GA, McLeod DS, Merges C, Diggs A and Plouét J: Localization of vascular endothelial growth factor in human retina and choroid. Arch Ophthalmol. 114:971–977. 1996. View Article : Google Scholar : PubMed/NCBI
24	Vincenti V, Cassano C, Rocchi M and Persico MG: Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation. 93:1493–1495. 1996. View Article : Google Scholar
25	Neufeld G, Cohen T, Gengrinovitch S and Poltorak Z: Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 13:9–22. 1999.PubMed/NCBI
26	Shahbazi M, Fryer AA, Pravica V, et al: Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J Am Soc Nephrol. 13:260–264. 2002.PubMed/NCBI
27	Lambrechts D, Storkebaum E, Morimoto M, et al: VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet. 34:383–394. 2003. View Article : Google Scholar : PubMed/NCBI
28	Renner W, Kotschan S, Hoffmann C, Obermayer-Pietsch B and Pilger E: A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res. 37:443–448. 2000. View Article : Google Scholar : PubMed/NCBI
29	Krippl P, Langsenlehner U, Renner W, et al: A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. Int J Cancer. 106:468–471. 2003. View Article : Google Scholar : PubMed/NCBI
30	Watson CJ, Webb NJ, Bottomley MJ and Brenchley PE: Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine. 12:1232–1235. 2000. View Article : Google Scholar : PubMed/NCBI
31	Lam JS, Leppert JT, Figlin RA and Belldegrun AS: Role of molecular markers in the diagnosis and therapy of renal cell carcinoma. Urology. 66:1–9. 2005. View Article : Google Scholar : PubMed/NCBI
32	Haviv YS and Curiel DT: Gene therapy for renal cancer. Contrib Nephrol. 159:135–150. 2008. View Article : Google Scholar
33	Hainsworth JD, Sosman JA, Spigel DR, Edwards DL, Baughman C and Greco A: Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol. 23:7889–7896. 2005. View Article : Google Scholar : PubMed/NCBI